• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Deacylation studies in vitro on anisoylated plasminogen streptokinase activator complex.

作者信息

Ferres H, Hibbs M, Smith R A

机构信息

Beecham Pharmaceuticals Research Division, Great Burgh, Epsom.

出版信息

Drugs. 1987;33 Suppl 3:80-2. doi: 10.2165/00003495-198700333-00011.

DOI:10.2165/00003495-198700333-00011
PMID:3315616
Abstract
摘要

相似文献

1
Deacylation studies in vitro on anisoylated plasminogen streptokinase activator complex.对茴香酰化纤溶酶原链激酶激活剂复合物的体外脱酰基研究。
Drugs. 1987;33 Suppl 3:80-2. doi: 10.2165/00003495-198700333-00011.
2
Non-exchange of streptokinase from anisoylated plasminogen streptokinase activator complex and other acylated streptokinase-plasminogen complexes.链激酶从对氨甲酰纤溶酶原链激酶激活剂复合物及其他酰化链激酶 - 纤溶酶原复合物中的非交换。
Drugs. 1987;33 Suppl 3:75-9. doi: 10.2165/00003495-198700333-00010.
3
Fibrin binding. An essential property of anisoylated plasminogen streptokinase activator complex.纤维蛋白结合。茴香酰化纤溶酶原链激酶激活剂复合物的一项基本特性。
Drugs. 1987;33 Suppl 3:93-6. doi: 10.2165/00003495-198700333-00014.
4
Pharmacology of anistreplase.茴香酰化纤溶酶原链激酶激活剂复合物的药理学
Clin Cardiol. 1990 Mar;Suppl 5:V3-10; discussion V27-32. doi: 10.1002/clc.4960131303.
5
Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.酰化纤溶酶原-链激酶激活剂复合物：溶栓治疗的新方法。
Pharmacotherapy. 1990;10(2):115-26.
6
Consequences of antibody binding in vitro on the pharmacological properties of anisoylated plasminogen streptokinase activator complex.体外抗体结合对茴香酰化纤溶酶原链激酶激活剂复合物药理特性的影响。
Drugs. 1987;33 Suppl 3:64-8. doi: 10.2165/00003495-198700333-00008.
7
Evidence for a sustained fibrinolytic response to anisoylated plasminogen streptokinase activator complex in vitro.体外对茴香酰化纤溶酶原链激酶激活剂复合物持续纤溶反应的证据。
Drugs. 1987;33 Suppl 3:83-7. doi: 10.2165/00003495-198700333-00012.
8
Evidence for the progressive uptake of anisoylated plasminogen streptokinase activator complex by clots in human plasma in vitro.体外人血浆中凝块对茴香酰化纤溶酶原链激酶激活剂复合物逐步摄取的证据。
Drugs. 1987;33 Suppl 3:51-6. doi: 10.2165/00003495-198700333-00006.
9
Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and in humans.茴香酰化纤溶酶原链激酶激活剂复合物及其他溶栓药物在动物和人体中的药代动力学特性。
Drugs. 1987;33 Suppl 3:88-92. doi: 10.2165/00003495-198700333-00013.
10
Acylated derivatives of streptokinase-plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis.链激酶 - 纤溶酶原激活剂复合物的酰化衍生物作为老年静脉血栓形成犬模型中的溶栓剂。
Thromb Haemost. 1985 Feb 18;53(1):56-9.

引用本文的文献

1
Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase.含链激酶溶栓药物的给药前抗体水平及疗效
Br Heart J. 1994 Sep;72(3):222-5. doi: 10.1136/hrt.72.3.222.
2
Pharmacokinetic optimisation of the treatment of embolic disorders.栓塞性疾病治疗的药代动力学优化
Clin Pharmacokinet. 1995 Jan;28(1):67-92. doi: 10.2165/00003088-199528010-00006.
3
Consequences of antibody binding in vitro on the pharmacological properties of anisoylated plasminogen streptokinase activator complex.体外抗体结合对茴香酰化纤溶酶原链激酶激活剂复合物药理特性的影响。

本文引用的文献

1
Mechanism of protein stabilization by glycerol: preferential hydration in glycerol-water mixtures.甘油对蛋白质的稳定机制：甘油 - 水混合物中的优先水合作用。
Biochemistry. 1981 Aug 4;20(16):4667-76. doi: 10.1021/bi00519a023.
2
Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy.酰基酶介导的纤维蛋白溶解：溶栓治疗的新方法。
Nature. 1981 Apr 9;290(5806):505-8. doi: 10.1038/290505a0.
3
Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis.酰基酶作为静脉血栓形成兔模型中的溶栓剂。
Drugs. 1987;33 Suppl 3:64-8. doi: 10.2165/00003495-198700333-00008.
4
Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.茴香酰化纤溶酶原链激酶激活剂复合物的临床前药理学评价
Drugs. 1987;33 Suppl 3:33-50. doi: 10.2165/00003495-198700333-00005.
5
Prodrugs.前体药物
Br J Clin Pharmacol. 1989 Nov;28(5):497-507. doi: 10.1111/j.1365-2125.1989.tb03535.x.
6
A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction.链激酶和茴香酰化纤溶酶原链激酶激活剂复合物在急性心肌梗死中的药代动力学特性比较。
Br J Clin Pharmacol. 1991 Feb;31(2):143-7. doi: 10.1111/j.1365-2125.1991.tb05502.x.
Thromb Haemost. 1982 Jun 28;47(3):269-74.
4
[Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct].
Klin Wochenschr. 1986 Aug 1;64(15):682-7. doi: 10.1007/BF01712052.
5
Clinical effects and kinetic properties of intravenous APSAC--anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction.静脉注射氨甲环酸纤溶酶原-链激酶激活剂复合物（BRL 26921）在急性心肌梗死中的临床疗效和动力学特性
Int J Cardiol. 1986 Apr;11(1):53-61. doi: 10.1016/0167-5273(86)90199-3.